Download PDF
Synlett 2003(13): 2021-2024  
DOI: 10.1055/s-2003-42040
LETTER
© Georg Thieme Verlag Stuttgart · New York

A Stereoselective Synthesis of (±)-3-Aryl-6-phenyl-1-oxa-7-azaspiro[4.5]-decanes

Piotr Raubo*, Janusz J. Kulagowski, Christopher J. Swain
Department of Medicinal Chemistry, Merck Sharp and Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex, CM20 2QR, UK
Fax: +44(1279)440187; e-Mail: piotr_raubo@merck.com;
Further Information

Publication History

Received 24 July 2003
Publication Date:
08 October 2003 (online)

    Permissions and Reprints All articles of this category

Abstract

A novel stereoselective synthesis of the 3-aryl-6-phenyl-1-oxa-7-azaspiro[4.5]decane ring is reported. Palladium(0)-mediated cyclocarbonylation of γ-iodoallylic alcohol is a key step in the formation of the spirocyclic ring.

Key words

spirocyclic compounds - lactones - stereoselective synthesis - regioselective lithiation - substance P (NK1 receptor) antagonist

    References

  • 1 Kramer MS. Cutler N. Feighner J. Shrivastava R. Carman J. Sramek JJ. Reines SA. Liu G. Snavely D. Wyatt-Knowles E. Hale JJ. Mills SG. MacCoss M. Swain CJ. Harrison T. Hill RG. Hefti F. Scolnick EM. Cascieri MA. Chicchi GG. Sadowski S. Williams AR. Hewson L. Smith D. Carlson EJ. Hargreaves RJ. Rupniak NMJ. Science  1998,  281:  1640 
    CrossrefGoogle Scholar
  • 2 Snider RM. Constantine JW. Lowe JA. Longo KP. Lebel WS. Woody HA. Drozda SE. Desai MC. Vinick FJ. Spencer RW. Hess H.-J. Science  1991,  251:  435 
    Google Scholar
  • 3 Seward EM. Swain CJ. Expert Opin. Ther. Pat.  1999,  9:  571 
    Google Scholar
  • For recent advances, see:
  • 4a Shaw D. Chicchi GG. Elliott JM. Kurtz M. Morrison D. Ridgill MP. Szeto N. Watt AP. Williams AR. Swain CJ. Bioorg. Med. Chem. Lett.  2001,  11:  3031 
    Google Scholar
  • 4b Elliott JM. Castro JL. Chicchi GG. Cooper LC. Dinnell K. Hollingworth GJ. Ridgill MP. Rycroft W. Kurtz MM. Shaw DE. Swain CJ. Tsao K.-L. Yang L. Bioorg. Med. Chem. Lett.  2002,  12:  1755 
    Google Scholar
  • 4c Cooper LC. Carlson EJ. Castro JL. Chicchi GG. Dinnell K. Di Salvo J. Elliott JM. Hollingworth GJ. Kurtz MM. Ridgill MP. Rycroft W. Tsao K.-L. Swain CJ. Bioorg. Med. Chem. Lett.  2002,  12:  1759 
    Google Scholar
  • 4d Seward EM. Carlson E. Harrison T. Haworth KE. Herbert R. Kelleher FJ. Kurtz MM. Moseley J. Owen SN. Owens AP. Sadowski SJ. Swain CJ. Williams BJ. Bioorg. Med. Chem. Lett.  2002,  12:  2515 
    Google Scholar
  • 4e Williams BJ. Cascieri MA. Chicchi GG. Harrison T. Owens AP. Owen SN. Rupniak NMJ. Tattersall DF. Williams A. Swain CJ. Bioorg. Med. Chem. Lett.  2002,  12:  2719 
    Google Scholar
  • 4f Gale JD. O’Neill BT. Humphrey JM. Expert Opin. Ther. Pat.  2001,  11:  1837 
    Google Scholar
  • 5 Maligres PE. Waters MM. Lee J. Reamer RA. Askin D. Ashwood MS. Cameron M. J. Org. Chem.  2002,  67:  1093 
    CrossrefGoogle Scholar
  • 6a Kulagowski JJ. Curtis NR. Swain CJ. Williams BJ. Org. Lett.  2001,  3:  667 
    Google Scholar
  • 6b Wallace DJ. Bulger PG. Kennedy DJ. Ashwood MS. Cottrell IF. Dolling U.-H. Synlett  2001,  3:  357 
    Google Scholar
  • 7 Kersey ID. Fishwick CWG. Findlay JBC. Ward P. Bioorg. Med. Chem. Lett.  1995,  5:  1271 
    CrossrefGoogle Scholar
  • 8 Hollingworth GJ. Dinnell K. Dickinson LC. Elliott JM. Kulagowski JJ. Swain CJ. Thomson CG. Tetrahedron Lett.  1999,  40:  2633 
    CrossrefGoogle Scholar
  • 9 Ohira S. Synth. Commun.  1989,  19:  561 
    CrossrefGoogle Scholar
  • 12 El AB. Alper H. J. Org. Chem.  1991,  56:  5357 
    Google Scholar
  • 13 Cowell A. Stille JK. J. Am. Chem. Soc.  1980,  102:  4193 
    CrossrefGoogle Scholar
  • 15 Baker R, Curtis NR, Elliott JM, Harrison T, Hollingworth GJ, Jackson PS, Kulagowski JJ, Seward EM, Swain CJ, and Williams BJ. inventors; WO Patent  97/49710.  ; Chem. Abstr. 1998, 128, 88921
10

Experimental Procedure for the Preparation of 3: A solution of EtMgBr in THF (1 M, 4.1 mL, 4.1 mmol) was added dropwise to a stirred solution of 5 (1.0 g, 4.1 mmol) in THF (10 mL) at r.t. After 30 min, the mixture was cooled to 0 °C and a solution of 4 (1.07 g, 3.9 mmol) in THF (10 ml) was added dropwise over 5 min. The mixture was stirred at 0 °C for 2 h and at r.t. overnight. After quenching with sat. aq NH4Cl, the mixture was extracted into 2-methylpentane. The combined organic extracts were dried (Na2SO4) and concentrated. The residue was purified on silica gel (2-methylpentane-Et2O) to give the alcohol 3 (1.17 g, 62%). 1H NMR (360 MHz, CDCl3): δ = 0.78-0.90 (m, 4 H), 1.32 (s, 9 H), 1.80 (m, 1 H), 2.00-2.15 (m, 2 H), 2.14 (s, 1 H), 2.22 (m, 1 H), 3.11 (m, 1 H), 3.78 (m, 1 H), 4.15 (dd, J = 5.6, 13.4 Hz, 1 H), 5.48 (s, 1 H), 7.15 (dd, J = 2.0, 9.2 Hz, 1 H), 7.17-7.40 (m, 6 H), 7.55 (d, J = 7.2 Hz, 2 H). Relative stereochemistry was assigned by 1H NMR experiments. [6a]

11

Experimental Procedure for the Preparation of 8: A solution of Red-Al® in toluene (0.9 mL, 3.1 mmol) was added dropwise to a stirred solution of 3 (1.17 g, 2.25 mmol) in anhyd Et2O (15 mL) at 0 °C. The ice bath was removed and the reaction mixture was stirred at r.t. for 2.5 h. The mixture was cooled to -78 °C and a solution of I2 (1 g, 4 mmol) in anhyd Et2O (10 mL) was added over 5 min. The reaction mixture was allowed to warm to r.t. over 2 h and quenched with sat. aq Na2SO3. The mixture was extracted into Et2O. The combined organic extracts were dried (Na2SO4) and concentrated. The residue was purified on silica gel (2-methylpentane-Et2O) to give the iodide 8 (1.14 g, 78%). 1H NMR (360 MHz, CDCl3): δ = 0.80-0.90 (m, 4 H), 1.34 (s, 9 H), 1.74-1.90 (m, 2 H), 2.05 (m, 1 H), 2.31 (dt, J = 5.2, 13.2 Hz, 1 H), 2.63 (s, 1 H), 3.18 (ddd, J = 5.8, 11.3, 13.6 Hz, 1 H), 3.78 (m, 1 H), 4.10 (m, 1 H), 5.39 (s, 1 H), 6.35 (s, 1 H), 7.06 (d, J = 2.8 Hz, 1 H), 7.20 (dd, J = 2.3, 8.5 Hz, 1 H), 7.22 (d, J = 8.9 Hz, 1 H), 7.25-7.40 (m, 4 H), 7.52 (d, J = 7.2 Hz, 2 H).

14

Experimental Procedure for the Preparation of 2: A solution of hydrazine in THF (0.07 mL, 0.07 mmol) was added, under an atmosphere of CO, to a stirred mixture of 8 (320 mg, 0.5 mmol), (Ph3P)2PdCl2 (50 mg, 0.07 mmol), K2CO3 (138 mg, 1 mmol) and THF (5 mL). The mixture was stirred at 50 °C for 5 d. After cooling to r.t., the mixture was diluted with Et2O and filtered through a pad of Celite. The filtrate was concentrated and the residue purified on silica gel (2-methylpentane-EtOAc) to give the lactone 2 (184 mg, 68%). 1H NMR (360 MHz, CDCl3): δ = 0.76-0.94 (m, 4 H), 1.39 (s, 9 H), 1.82-2.04 (m, 3 H), 2.30 (m, 1 H), 3.20 (dt, J = 4.8, 13.7 Hz, 1 H), 3.82 (m, 1 H), 4.22 (dd, J = 5.6, 13.4 Hz, 1 H), 5.25 (s, 1 H), 7.19 (dd, J = 1.4, 9.2 Hz, 1 H), 7.22-7.33 (m, 4 H), 7.39 (d, J = 7.3 Hz, 1 H), 7.98 (d, J = 2.9 Hz, 1 H), 8.08 (s, 1 H).

16

The spectral data exhibited by 1 was identical to reported. [15]